MacroGenics Future Growth

Future criteria checks 2/6

MacroGenics's earnings are forecast to decline at 20% per annum while its annual revenue is expected to grow at 25.5% per year. EPS is expected to decline by 17.3% per annum. Return on equity is forecast to be -63% in 3 years.

Key information

-20.0%

Earnings growth rate

-17.3%

EPS growth rate

Biotechs earnings growth	24.1%
Revenue growth rate	25.5%
Future return on equity	-63.0%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12

MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials

Feb 25

Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)

Feb 18

We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Nov 21

MacroGenics: Revisiting Our Pipeline And Investment Analysis

Aug 10

MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be

Aug 03

MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology

Jun 16

MacroGenics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Apr 30

Earnings and Revenue Growth Forecasts

NasdaqGS:MGNX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	97	-194	-163	-176	5
12/31/2025	140	-104	-154	-97	7
12/31/2024	71	-162	-138	-131	10
12/31/2023	59	-9	-80	-78	N/A
9/30/2023	121	50	-22	-21	N/A
6/30/2023	152	7	3	5	N/A
3/31/2023	165	-91	-45	-42	N/A
12/31/2022	152	-120	-91	-87	N/A
9/30/2022	93	-191	-175	-171	N/A
6/30/2022	67	-219	-182	-176	N/A
3/31/2022	72	-217	-179	-172	N/A
12/31/2021	77	-202	-150	-144	N/A
9/30/2021	116	-146	-103	-95	N/A
6/30/2021	119	-129	-113	-106	N/A
3/31/2021	108	-136	-102	-97	N/A
12/31/2020	105	-130	-118	-112	N/A
9/30/2020	77	-158	-148	-144	N/A
6/30/2020	78	-167	-140	-136	N/A
3/31/2020	68	-152	-152	-148	N/A
12/31/2019	64	-152	-139	-134	N/A
9/30/2019	55	-166	-127	-123	N/A
6/30/2019	57	-155	-150	-143	N/A
3/31/2019	65	-167	-164	-152	N/A
12/31/2018	60	-171	-178	-153	N/A
9/30/2018	197	-21	-49	-14	N/A
6/30/2018	178	-34	-49	-9	N/A
3/31/2018	160	-32	-24	18	N/A
12/31/2017	158	-20	-15	14	N/A
9/30/2017	10	-160	N/A	-126	N/A
6/30/2017	12	-147	N/A	-45	N/A
3/31/2017	91	-66	N/A	-47	N/A
12/31/2016	92	-59	N/A	-44	N/A
9/30/2016	95	-52	N/A	-40	N/A
6/30/2016	106	-34	N/A	-97	N/A
3/31/2016	32	-96	N/A	-89	N/A
12/31/2015	101	-20	N/A	-14	N/A
9/30/2015	98	-11	N/A	-10	N/A
6/30/2015	102	1	N/A	-16	N/A
3/31/2015	104	10	N/A	5	N/A
12/31/2014	48	-38	N/A	-33	N/A
9/30/2014	57	-20	N/A	-14	N/A
6/30/2014	59	-15	N/A	1	N/A
3/31/2014	62	0	N/A	-4	N/A
12/31/2013	58	0	N/A	-14	N/A
9/30/2013	53	N/A	N/A	5	N/A
6/30/2013	49	0	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGNX's revenue (25.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: MGNX's revenue (25.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MGNX is forecast to be unprofitable in 3 years.

MacroGenics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 21%

Price target increased by 9.9% to US$16.00

Price target increased by 8.1% to US$14.78

Price target increased by 12% to US$14.33

Consensus EPS estimates increase by 17%, revenue downgraded

Consensus revenue estimates decrease by 25%, EPS upgraded

Recent updates

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

New minor risk - Share price stability

Consensus revenue estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target increased by 9.9% to US$16.00

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

President exercised options and sold US$250k worth of stock

MacroGenics: Trying To Build A Better Everything

Price target increased by 8.1% to US$14.78

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Price target increased by 12% to US$14.33

Insider notifies of intention to sell stock

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment improves as stock rises 18%

Consensus revenue estimates decrease by 25%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Investor sentiment deteriorates as stock falls 15%

Insider recently bought US$74k worth of stock

Investor sentiment deteriorates as stock falls 16%

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates fall by 13%

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Price target increased by 11% to US$11.75

Consensus revenue estimates increase by 42%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus EPS estimates fall by 10%

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Price target decreased to US$10.40

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Price target increased to US$12.33

Consensus revenue estimates increase by 11%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus forecasts updated

MacroGenics: No Near-Term Catalysts

Price target decreased to US$10.72

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 33%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics Q2 2022 Earnings Preview

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Price target decreased to US$25.33

MacroGenics halts mid-stage head and neck cancer study after fatalities

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Senior VP recently bought US$99k worth of stock

MacroGenics, Inc. Announces Management Changes

President exercised options to buy US$208k worth of stock.

Consensus revenue estimates fall by 31%